Adiponectin: A relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?

M. Bouskila, U. B. Pajvani, P. E. Scherer

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The potent insulin-sensitizing effects of peroxisome proliferator-activated receptor γ (PPARγ) agonists are well established. However, it is still a matter of intense debate as to which tissue(s) represent the most critical sites of action for PPARγ agonists, and what the relevant target genes are that ultimately mediate the improvements in insulin sensitivity. The cell type with the highest levels of PPARγ is the adipocyte, and as such the adipocyte is an excellent candidate cell to look for critical mediators of PPARγ agonist action. Adiponectin, an adipocyte-specific secretory protein, is upregulated in response to PPARγ agonist exposure, and its serum levels consequently increase significantly. Genetic, pharmacological and clinical studies have demonstrated potent insulin-sensitizing effects of adiponectin. Here, we summarize the evidence that implicates adiponectin as a critical mediator of PPARγ-agonist-mediated improvements in insulin sensitivity, particularly in the context of PPARγ-agonist-mediated enhancements of hepatic insulin sensitivity.

Original languageEnglish (US)
JournalInternational Journal of Obesity
Volume29
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2005

Fingerprint

Peroxisome Proliferator-Activated Receptors
adiponectin
Adiponectin
insulin resistance
agonists
Insulin Resistance
liver
Liver
adipocytes
Adipocytes
insulin
Insulin
peroxisome proliferator-activated receptors
clinical trials
Pharmacology
cells
Serum
Genes

Keywords

  • Acrp30
  • Gluconeogenesis
  • Rosiglitazone

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Adiponectin : A relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? / Bouskila, M.; Pajvani, U. B.; Scherer, P. E.

In: International Journal of Obesity, Vol. 29, No. SUPPL. 1, 03.2005.

Research output: Contribution to journalArticle

@article{ebe5a2f55e5449b38df9fc6836cebd99,
title = "Adiponectin: A relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?",
abstract = "The potent insulin-sensitizing effects of peroxisome proliferator-activated receptor γ (PPARγ) agonists are well established. However, it is still a matter of intense debate as to which tissue(s) represent the most critical sites of action for PPARγ agonists, and what the relevant target genes are that ultimately mediate the improvements in insulin sensitivity. The cell type with the highest levels of PPARγ is the adipocyte, and as such the adipocyte is an excellent candidate cell to look for critical mediators of PPARγ agonist action. Adiponectin, an adipocyte-specific secretory protein, is upregulated in response to PPARγ agonist exposure, and its serum levels consequently increase significantly. Genetic, pharmacological and clinical studies have demonstrated potent insulin-sensitizing effects of adiponectin. Here, we summarize the evidence that implicates adiponectin as a critical mediator of PPARγ-agonist-mediated improvements in insulin sensitivity, particularly in the context of PPARγ-agonist-mediated enhancements of hepatic insulin sensitivity.",
keywords = "Acrp30, Gluconeogenesis, Rosiglitazone",
author = "M. Bouskila and Pajvani, {U. B.} and Scherer, {P. E.}",
year = "2005",
month = "3",
doi = "10.1038/sj.ijo.0802908",
language = "English (US)",
volume = "29",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Adiponectin

T2 - A relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?

AU - Bouskila, M.

AU - Pajvani, U. B.

AU - Scherer, P. E.

PY - 2005/3

Y1 - 2005/3

N2 - The potent insulin-sensitizing effects of peroxisome proliferator-activated receptor γ (PPARγ) agonists are well established. However, it is still a matter of intense debate as to which tissue(s) represent the most critical sites of action for PPARγ agonists, and what the relevant target genes are that ultimately mediate the improvements in insulin sensitivity. The cell type with the highest levels of PPARγ is the adipocyte, and as such the adipocyte is an excellent candidate cell to look for critical mediators of PPARγ agonist action. Adiponectin, an adipocyte-specific secretory protein, is upregulated in response to PPARγ agonist exposure, and its serum levels consequently increase significantly. Genetic, pharmacological and clinical studies have demonstrated potent insulin-sensitizing effects of adiponectin. Here, we summarize the evidence that implicates adiponectin as a critical mediator of PPARγ-agonist-mediated improvements in insulin sensitivity, particularly in the context of PPARγ-agonist-mediated enhancements of hepatic insulin sensitivity.

AB - The potent insulin-sensitizing effects of peroxisome proliferator-activated receptor γ (PPARγ) agonists are well established. However, it is still a matter of intense debate as to which tissue(s) represent the most critical sites of action for PPARγ agonists, and what the relevant target genes are that ultimately mediate the improvements in insulin sensitivity. The cell type with the highest levels of PPARγ is the adipocyte, and as such the adipocyte is an excellent candidate cell to look for critical mediators of PPARγ agonist action. Adiponectin, an adipocyte-specific secretory protein, is upregulated in response to PPARγ agonist exposure, and its serum levels consequently increase significantly. Genetic, pharmacological and clinical studies have demonstrated potent insulin-sensitizing effects of adiponectin. Here, we summarize the evidence that implicates adiponectin as a critical mediator of PPARγ-agonist-mediated improvements in insulin sensitivity, particularly in the context of PPARγ-agonist-mediated enhancements of hepatic insulin sensitivity.

KW - Acrp30

KW - Gluconeogenesis

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=14844327755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844327755&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0802908

DO - 10.1038/sj.ijo.0802908

M3 - Article

C2 - 15711577

AN - SCOPUS:14844327755

VL - 29

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - SUPPL. 1

ER -